Compare Godaddy Inc (GDDY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs 10X Genomics Inc — how do they compare? Godaddy Inc trades at $104.37 (market cap $13.07B), while 10X Genomics Inc trades at $80.88 (market cap $10.07B). The key difference: Godaddy Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and 10X Genomics Inc for 91 Days on average.
| GDDY | TXG | |
|---|---|---|
Market Cap | $13.07B | $10.07B |
Volume | 1,831,274 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $135.18 | $97.74 |
52-Week Low | $75.07 | $11.48 |
Typical Hold Time | 64 Days | 91 Days |
Enterprise Value | $15.75B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $104.37, up 7.37% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows robust fundamentals with a 17.83% net income margin and revenue growth to $4.95 billion in 2025. However, a class action lawsuit filed in September 2026 alleging securities fraud during September 2025 to February 2026 has created negative sentiment, though analyst consensus remains predominantly buy-rated.
The outlook is mixed; strong profitability and consistent earnings beats support upside potential, but legal risks and a current price above the $96.20 consensus target warrant caution. Key risks include litigation outcomes and competitive pressures in web services, while institutional analyst support at 57.9% buy ratings provides a cushion against near-term volatility.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
